Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cees J Tack

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
BMC Public Health|November 8, 2012
The Diabetes Pearl: Diabetes biobanking in The NetherlandsEsther van't Riet, Miranda T Schram, Evertine J Abbink, et al.
Molecular Medicine (Cambridge, Mass.)|May 4, 2019
Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetesAndreea-Manuela Mirea, Erik J M Toonen, Inge van den Munckhof, et al.
Nature Communications|January 13, 2015
Corrigendum: IL-37 protects against obesity-induced inflammation and insulin resistanceDov B Ballak, Janna A van Diepen, Alexander R Moschen, et al.
Nature Communications|September 4, 2014
IL-37 protects against obesity-induced inflammation and insulin resistanceDov B Ballak, Janna A van Diepen, Alexander R Moschen, et al.
BMJ Open Diabetes Research & Care|October 7, 2020
Sex differences in cardiometabolic risk factors, pharmacological treatment and risk factor control in type 2 diabetes: findings from the Dutch Diabetes Pearl cohortMarit de Jong, Marieke J Oskam, Simone J S Sep, et al.
Nature Medicine|May 30, 2006
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistanceMihai G Netea, Leo A B Joosten, Eli Lewis, et al.
Cell Metabolism|November 27, 2010
The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivityRinke Stienstra, Leo A B Joosten, Tim Koenen, et al.
Diabetes, Obesity & Metabolism|October 5, 2018
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trialStephen C Bain, Ofri Mosenzon, Rosario Arechavaleta, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
BMC Public Health|November 8, 2012
The Diabetes Pearl: Diabetes biobanking in The NetherlandsEsther van't Riet, Miranda T Schram, Evertine J Abbink, et al.
Molecular Medicine (Cambridge, Mass.)|May 4, 2019
Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetesAndreea-Manuela Mirea, Erik J M Toonen, Inge van den Munckhof, et al.
Nature Communications|January 13, 2015
Corrigendum: IL-37 protects against obesity-induced inflammation and insulin resistanceDov B Ballak, Janna A van Diepen, Alexander R Moschen, et al.
Nature Communications|September 4, 2014
IL-37 protects against obesity-induced inflammation and insulin resistanceDov B Ballak, Janna A van Diepen, Alexander R Moschen, et al.
BMJ Open Diabetes Research & Care|October 7, 2020
Sex differences in cardiometabolic risk factors, pharmacological treatment and risk factor control in type 2 diabetes: findings from the Dutch Diabetes Pearl cohortMarit de Jong, Marieke J Oskam, Simone J S Sep, et al.
Nature Medicine|May 30, 2006
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistanceMihai G Netea, Leo A B Joosten, Eli Lewis, et al.
Cell Metabolism|November 27, 2010
The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivityRinke Stienstra, Leo A B Joosten, Tim Koenen, et al.
Diabetes, Obesity & Metabolism|October 5, 2018
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trialStephen C Bain, Ofri Mosenzon, Rosario Arechavaleta, et al.
Pageof 19